On 1 July, the Alzheimer’s Disease Data Initiative (ADDI) released its first ever newsletter, in which EPAD is featured as a key partner and the first project to place its entire dataset onto the Alzheimer’s Disease (AD) Workbench. From January 2015 until February 2020, the EPAD Longitudinal Cohort Study (LCS) screened over 2,000 participants across nine European countries to collect a wide range of cognitive, clinical, neuroimaging and biomarker data. A total of 2,096 participants were screened. From these 2,096 participants, EPAD followed up with 1,225 after one year, 421 after two years and 121 after three years. As the project progressed, four datasets have freely been made available ensuring the use of the data for the Alzheimer’s disease research community worldwide.
The latest and final EPAD dataset called Version.IMI. (V.IMI) is now available in the AD Workbench and will provide even greater value to the global neuroscience research community. All the data collected and processed during the IMI period of EPAD have been included in this V.IMI release. EPAD members are pleased that this incredibly rich data source, including data that have been collected annually from research participants throughout their participation in the LCS, has been incorporated into the AD Workbench. It is an important step in continuing to share the LCS data in the long-term and ensuring that this valuable resource is used by the research community to generate as much knowledge as possible. The ADDI platform will provide a crucial acceleration in scientific breakthroughs on the causes, diagnosis, and prevention of Alzheimer’s disease.
You can read the ADDI newsletter here.
